Cargando…
Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial
BACKGROUND: Tranilast is a potential NLRP3 inflammasome inhibitor that may relieve progressive inflammation due to COVID-19. AIM OF THE STUDY: To evaluate the therapeutic effects of Tranilast in combination with antiviral drugs in non-ICU-admitted hospitalized patients with COVID-19. METHODS: This s...
Autores principales: | Saeedi-Boroujeni, Ali, Nashibi, Roohangiz, Ghadiri, Ata A., Nakajima, Motowo, Salmanzadeh, Shokrollah, Mahmoudian-Sani, Mohammad-Reza, Hanafi, Mohammad Ghasem, Sharhani, Asaad, Khodadadi, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919799/ https://www.ncbi.nlm.nih.gov/pubmed/35339280 http://dx.doi.org/10.1016/j.arcmed.2022.03.002 |
Ejemplares similares
-
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial
por: Shohan, Mojtaba, et al.
Publicado: (2022) -
Evaluation of the frequency of resistance to 2 drugs (Isoniazid and Rifampin) by molecular investigation and it's risk factors in new cases of smear positive pulmonary tuberculosis in health centers under the cover of Jundishapur University of Medical Sciences in 2017
por: Salmanzadeh, Shokrollah, et al.
Publicado: (2020) -
miRNA-223 as a regulator of inflammation and NLRP3 inflammasome, the main fragments in the puzzle of immunopathogenesis of different inflammatory diseases and COVID-19
por: Houshmandfar, Sheyda, et al.
Publicado: (2021) -
COVID-19 Pandemic along with Pandemic of Lifestyle-Associated Diseases Victimizes Patients in an Inflammation Context!
por: Saeedi-Boroujeni, Ali, et al.
Publicado: (2020) -
Anti-inflammatory potential of Quercetin in COVID-19 treatment
por: Saeedi-Boroujeni, Ali, et al.
Publicado: (2021)